Alnylam Pharmaceuticals (ALNY): Director exercised options on 3,780 units

3,780

Derivative units

Traded

Nov 10, 2026

Filed

Nov 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 2, 2026InsiderOfficer sold ~$399K of ALNY shares in the open market
2. Oct 29, 2026Company filing · Form 8-K · ResultsReported its results
3. Oct 30, 20265% stakeVanguard Portfolio Management reported a passive stake (13G) of 5.0%
4. Nov 2, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On November 4, 2026, Alnylam Pharmaceuticals, Inc. (the “Company”) announced that Tolga Tanguler will depart from his role as the Company’s Executive Vice President, Chief Commercialization Officer in December 2026.”
5. Nov 5, 20265% stakeFMR LLC reported a passive stake (13G) of 9.5%
6. Nov 9, 2026Insider · First insider buy since Oct 2024Director purchased ~$300K of ALNY shares in the open market
7. Nov 10, 2026Insider · Their first buy on recordDirector purchased ~$244K of ALNY shares in the open market

What came next

1. Nov 13, 20265% stakeCapital World Investors reported a passive stake (13G) of 10.4%
2. Nov 13, 20265% stakeCapital Research Global Investors reported a passive stake (13G) of 8.2%

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Alnylam Pharmaceuticals

For Alnylam Pharmaceuticals, OQRO holds 4 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALNY page.

Other recent filings by David E I Pyott, Director

• SEC Form 4 at Alnylam Pharmaceuticals (ALNY)Mar 25, 2025

The full history of David E I Pyott, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Alnylam Pharmaceuticals

• SEC Form 4Nov 12, 2026
• SEC Form 4Nov 12, 2026
• SEC Form 4Oct 7, 2026
• SEC Form 144Oct 2, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its ALNY page.